Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 7,689 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $30.03, for a total value of $230,900.67. Following the transaction, the senior vice president now owns 27,265 shares of the company’s stock, valued at approximately $818,767.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Santiago Arroyo also recently made the following trade(s):
- On Tuesday, January 21st, Santiago Arroyo sold 1,235 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $30.08, for a total value of $37,148.80.
NASDAQ:MNTA opened at $31.88 on Friday. Momenta Pharmaceuticals, Inc. has a 12-month low of $9.51 and a 12-month high of $32.37. The firm has a market capitalization of $3.16 billion, a P/E ratio of -14.69 and a beta of 2.01. The business has a 50 day simple moving average of $26.17 and a 200 day simple moving average of $17.38.
A number of research firms recently issued reports on MNTA. Piper Sandler boosted their price objective on Momenta Pharmaceuticals from to in a research report on Wednesday, February 5th. Stifel Nicolaus restated a “buy” rating and set a $43.00 price objective (up previously from $29.00) on shares of Momenta Pharmaceuticals in a research report on Monday, January 27th. SunTrust Banks boosted their price objective on Momenta Pharmaceuticals to and gave the company a “buy” rating in a research report on Wednesday, January 15th. Wells Fargo & Co began coverage on Momenta Pharmaceuticals in a research report on Wednesday, November 6th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. upgraded Momenta Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $14.00 to $30.00 in a research report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $31.79.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Read More: What is the definition of arbitrage?
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.